

IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Currently Amended): A peptide ~~consisting of~~ comprising 10 - 25 contiguous amino acids in the amino acid sequence of human WT1 shown in SEQ ID NO: 1, which binds to HLA-DRB1*0405 and induces helper T cells.

Claim 2 (Currently Amended): The peptide of claim 1, which comprises an amino acid sequence set forth in any one of SEQ ID NOS: 2 - ~~[[23]]~~ 24.

Claim 3 (Original): The peptide of claim 2, which comprises the amino acid sequence set forth in SEQ ID NO: 24.

Claim 4 (Currently Amended): A peptide of 10 - 25 amino acids, which comprises an amino acid sequence wherein the amino acid residue at position 1, 4, 6 and/or 9 of an amino acid sequence set forth in any one of SEQ ID NOS: 2 - ~~[[23]]~~ 24 is substituted by another amino acid residue, and which binds to an HLA-DRB1*0405 and induces helper T cells.

Claim 5 (Currently Amended): The peptide of claim 4, which comprises an amino acid sequence wherein the amino acid residue at position 1, 4, 6 and/or 9 of an amino acid sequence set forth in any one of SEQ ID NOS: 2 - ~~[[23]]~~ 24 is substituted by ~~[[an]]~~ at least one amino acid residue selected from the ~~following amino acids~~ group consisting of:

phenylalanine, tyrosine, tryptophan, valine, isoleucine, leucine and methionine for the position 1;

valine, isoleucine, leucine, methionine, aspartic acid and glutamic acid for the position 4;

asparagine, serine, threonine, glutamine, lysine and aspartic acid for the position 6; and

aspartic acid, glutamic acid and glutamine for the position 9.

Claim 6 (Currently Amended): The peptide of claim 5, which comprises an amino acid sequence wherein the amino acid residue at position 3, 6, 8 and/or 11 of the amino acid sequence set forth in SEQ ID NO: 24 is substituted by ~~[[an]]~~ at least one amino acid residue selected from the ~~following amino acids group consisting of:~~

phenylalanine, tryptophan, valine, isoleucine, leucine and methionine for the position 3;
valine, isoleucine, methionine, aspartic acid and glutamic acid for the position 6;
asparagine, serine, threonine, glutamine, lysine and aspartic acid for the position 8; and
aspartic acid, glutamic acid and glutamine for the position 11.

Claim 7 (Previously Presented): A peptide comprising a peptide described in claim 1 together with a cancer antigen peptide.

Claim 8 (Previously Presented): A polynucleotide encoding a peptide described in claim 1.

Claim 9 (Currently Amended): An expression vector ~~containing~~ comprising the polynucleotide described in claim 8.

Claim 10 (Currently Amended): A cell ~~containing~~ comprising the expression vector described in claim 9.

Claim 11 (Previously Presented): A process for producing a peptide described in claim 1, which comprises culturing the cell described in claim 10 under the condition where the peptide can be expressed.

Claim 12 (Previously Presented): An antibody which specifically binds to a peptide described in claim 1.

Claim 13 (Previously Presented): A pharmaceutical composition which comprises a peptide described in claim 1, an expression vector described in 9 or a cell described in claim 10, in association with a pharmaceutically acceptable carrier.

Claim 14 (Original): The pharmaceutical composition of claim 13, which is a therapeutic or preventive agent for cancer.

Claim 15 (Previously Presented): The pharmaceutical composition of claim 13, which is an inducer of helper T cells, and which comprises a peptide described in claim 1; an expression vector described in claim 9 related to a peptide of claim 1; or a cell described in claim 10 related to a peptide of claim 1, in association with a pharmaceutically acceptable carrier.

Claim 16 (Previously Presented): The pharmaceutical composition of claim 13, which is an enhancer of cancer vaccine efficacy, and which comprises a peptide described in claim 1; an expression vector described in claim 9 related to a peptide of claim 1; or a cell described in claim 10 related to a peptide of claim 1, in association with a pharmaceutically acceptable carrier.

Claim 17 (Original): The pharmaceutical composition of claim 13, which is a therapeutic or preventive agent for cancer, and which comprises a peptide described in claim 7; an expression vector described in claim 9 related to a peptide of claim 7; or a cell described in claim 10 related to a peptide of claim 7, in association with a pharmaceutically acceptable carrier.

Claim 18 (Canceled).

Claim 19 (Previously Presented): A method of treating or preventing cancer, which comprises administering a peptide described in claim 1, an expression vector described in claim 9 or a cell described in claim 10 to a subject in need thereof.

Claim 20 (Previously Presented): A pharmaceutical composition which comprises a peptide described in claim 1 in combination with a cancer antigen peptide.

Claim 21 (Original): The pharmaceutical composition of claim 20, which is used for treating or preventing cancer.

Claim 22 (Previously Presented): A kit for treating or preventing cancer, which comprises a pharmaceutical composition comprising a peptide of claim 1 in association with a pharmaceutically acceptable carrier, and a pharmaceutical composition comprising a cancer antigen peptide in association with a pharmaceutically acceptable carrier.

Claim 23 (Canceled).

Claim 24 (Previously Presented): A method of treating or preventing cancer, which comprises administering a peptide of claim 1 in combination with a cancer antigen peptide to a subject in need thereof.

Claim 25 (New): The peptide of Claim 2, which consists of the amino acid sequence of SEQ ID NO: 3.

Claim 26 (New): A peptide comprising the amino acid sequence of SEQ ID NO: 24.